← Back to Clinical Trials
Recruiting NCT05333367

NCT05333367 MORPHEE : Mechanisms of Cell Death Induced by Extracorporeal Photochemotherapy

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05333367
Status Recruiting
Phase
Sponsor Centre Hospitalier Universitaire de Besancon
Condition Cutaneous T-Cell Lymphoma
Study Type INTERVENTIONAL
Enrollment 20 participants
Start Date 2022-04-15
Primary Completion 2025-07

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 85 Years
Study Type INTERVENTIONAL
Interventions
Samples collection

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 20 participants in total. It began in 2022-04-15 with a primary completion date of 2025-07.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The objective of this study is to describe the type of cell death induced by extracorporeal photochemotherapy, depending on the cell type, using a panel of complementary analysis techniques.

Eligibility Criteria

Inclusion Criteria: * Adult patients * Treated with ECP for at least 1 month, for control of GVHD in hematopoietic cell allograft (acute or chronic GVHD), treatment and control of cellular or humoral rejection in solid organ transplantation (heart, lung, kidney) or in the treatment of cutaneous T-cell lymphoma Exclusion Criteria: * Subjects with limited legal capacity. * Subjects judged by the investigator to be unlikely to comply with study procedures * Subjects with no social security coverage. * Pregnant women. * Subjects still in the exclusion period of another study, or according to the national registry of clinical trial participants.

Contact & Investigator

Central Contact

Charline VAUCHY, PhD

✉ cvauchy@chu-besancon.fr

📞 +33381218875

Frequently Asked Questions

Who can join the NCT05333367 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Cutaneous T-Cell Lymphoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05333367 currently recruiting?

Yes, NCT05333367 is actively recruiting participants. Contact the research team at cvauchy@chu-besancon.fr for enrollment information.

Where is the NCT05333367 trial being conducted?

This trial is being conducted at Besançon, France.

Who is sponsoring the NCT05333367 clinical trial?

NCT05333367 is sponsored by Centre Hospitalier Universitaire de Besancon. The trial plans to enroll 20 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology